Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)

被引：0
|
作者：
Verzoni, E. [1 ]
Procopio, G. [1 ]
Bottiglieri, A. [1 ]
Stellato, M. [1 ]
Rametta, A. [1 ]
Zucali, P. A. [2 ]
Perrucci, B. [3 ]
Fornarini, G. [4 ]
Buti, S. [5 ,6 ]
Maruzzo, M. [7 ]
Cova, A. [8 ]
Squarcina, P. [8 ]
Lalli, L. [8 ]
Mereu, A. [8 ]
Cerioli, N. [8 ]
Agnelli, L. [9 ]
Todoerti, K. [10 ]
Busico, A. [10 ]
Rivoltini, L. [8 ]
Huber, V. [8 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy
[2] Humanitas Univ, Dept Oncol, Dept Biomed Sci, IRCCS,Humanitas Clin & Res Ctr, Rozzano, Italy
[3] ASST Cremona Azienda Socio Sanit Terr, Med Oncol Dept, Cremona, Italy
[4] IRCCS Osped Policlin San Martino, Hematol & Oncol Dept, Genoa, Italy
[5] Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy
[6] Univ Parma, Dept Med & Surg, Parma, Italy
[7] Veneto Inst Oncol IOV IRCCS, Oncol Unit 1, Padua, Italy
[8] Fdn IRCCS Ist Nazl Tumori, Unit Immunotherapy Human Tumors, Milan, Italy
[9] Fdn IRCCS Ist Nazl Tumori, Dept Adv Diagnost, Mol Tumor Board, Milan, Italy
[10] Fdn IRCCS Ist Nazl Tumori, Dept Innovat Diagnost, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1901P
引用
收藏
页码：S1022 / S1023
页数：2
相关论文
共 16 条
  • [1] The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (Δ-Meet-URO analysis).
    Rebuzzi, Sara Elena
    Signori, Alessio
    Buti, Sebastiano
    Banna, Giuseppe Luigi L.
    Stellato, Marco
    Santini, Daniele
    Basso, Umberto
    De Giorgi, Ugo
    Chiellino, Silvia
    Salfi, Alessia
    Zucali, Paolo Andrea
    Masini, Cristina
    Naglieri, Emanuele
    Procopio, Giuseppe
    Milella, Michele
    Boccardo, Francesco
    Fratino, Lucia
    Pipitone, Stefania
    Porta, Camillo
    Fornarini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-URO 8 study).
    Verzoni, Elena
    Huber, Veronica
    Cova, Agata
    Squarcina, Paola
    Frati, Paola
    Lalli, Luca
    Stroscia, Martina
    Bottiglieri, Achille
    Fotia, Giuseppe
    Sepe, Pierangela
    Stellato, Marco
    Zucali, Paolo Andrea
    Perrucci, Bruno
    Buti, Sebastiano
    Maruzzo, Marco
    Vittimberga, Isabella
    Fornarini, Giuseppe
    Rivoltini, Licia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
    Brunelli, M.
    Buti, S.
    Rebuzzi, S. E.
    Milella, M.
    Vellone, V.
    Bersanelli, M.
    Maruzzo, M.
    Basso, U.
    Signori, A.
    Martelli, V.
    Catalano, F.
    Damassi, A.
    Murianni, V.
    Merler, S.
    Casartelli, C.
    Fornarini, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S607 - S608
  • [4] Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
    Salas, R. N.
    Ireland, J. L.
    Ko, J. S.
    Elson, P.
    Garcia, J. A.
    Wood, L.
    Bukowski, R. M.
    Rini, B. I.
    Finke, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study
    Rebuzzi, S. E.
    Rescigno, P.
    Signori, A.
    Brunelli, M.
    Galuppini, F.
    Vellone, V. G.
    Gaggero, G.
    Maruzzo, M.
    Milella, M.
    Vignani, F.
    Cavo, A.
    Basso, U.
    Catalano, F.
    Murianni, V.
    Cremante, M.
    Damassi, A.
    Obispo, M. A. Llaja
    Banna, G. L.
    Buti, S.
    Fornarini, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1221 - S1222
  • [6] The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
    Rebuzzi, Sara Elena
    Signori, Alessio
    Stellato, Marco
    Santini, Daniele
    Maruzzo, Marco
    De Giorgi, Ugo
    Pedrazzoli, Paolo
    Galli, Luca
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Carella, Claudia
    Procopio, Giuseppe
    Milella, Michele
    Boccardo, Francesco
    Fratino, Lucia
    Sabbatini, Roberto
    Ricotta, Riccardo
    Panni, Stefano
    Massari, Francesco
    Soraru, Mariella
    Santoni, Matteo
    Cortellini, Alessio
    Prati, Veronica
    Soto Parra, Hector Jose
    Atzori, Francesco
    Di Napoli, Marilena
    Caffo, Orazio
    Messina, Marco
    Morelli, Franco
    Prati, Giuseppe
    Nole, Franco
    Vignani, Francesca
    Cavo, Alessia
    Roviello, Giandomenico
    Llaja Obispo, Miguel Angel
    Porta, Camillo
    Buti, Sebastiano
    Fornarini, Giuseppe
    Banna, Giuseppe Luigi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
    Rebuzzi, S. E.
    Signori, A.
    Buti, S.
    Maruzzo, M.
    De Giorgi, U. F. F.
    Zucali, P. A.
    Procopio, G.
    Fratino, L.
    Pipitone, S.
    Mollica, V.
    Soraru, M.
    Chiellino, S.
    Lipari, H.
    Galli, L.
    Masini, C.
    Naglieri, E.
    Milella, M.
    Ricotta, R.
    Banna, G. L.
    Fornarini, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1020 - S1020
  • [8] Impact of microbiome modulation on serum cytokine profile in a randomized, phase I trial of cabozantinib/nivolumab (cabo/nivo) with or without CBM588 in pts with metastatic renal cell carcinoma (mRCC)
    Li, Yu Jun
    Ebrahimi, Hedyeh
    Meza, Luis
    Malhotra, Jasnoor
    Li, Xiaochen
    Dizman, Nazli
    Dorff, Tanya
    Frankel, Paul
    Llamas-Quitiquit, Marian
    Hsu, JoAnn
    Zengin, Zeynep
    Alcantara, Marice
    Castro, Daniela
    Mercier, Benjamin
    Chawla, Neal
    Chehrazi-Raffle, Alexander
    Barragan-Carrillo, Regina
    Gillece, John
    Trent, Jeffrey
    Lee, Peter
    Parks, Thomas
    Takahashi, Motomichi
    Hayashi, Atsushi
    Caporaso, J. Gregory
    Lee, Keehoon
    Tripathi, Abhishek
    Pal, Sumanta
    ONCOLOGIST, 2024, 29 : S36 - S37
  • [9] Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study).
    Catalano, Fabio
    Murianni, Veronica
    Rebuzzi, Sara Elena
    Galuppini, Francesca
    Buti, Sebastiano
    Brunelli, Matteo
    Maruzzo, Marco
    Dei Tos, Angelo Paolo
    Basso, Umberto
    Banna, Giuseppe Lugi
    Signori, Alessio
    Sbaraglia, Marta
    Damassi, Alessandra
    Cremante, Malvina
    Puglisi, Silvia
    Gandini, Annalice
    Rebuzzi, Marta
    Mosca, Alessandra
    Fornarini, Giuseppe
    Rescigno, Pasquale
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
    Rebuzzi, S. E.
    Signori, A.
    Maruzzo, M.
    Tortora, G.
    Galli, L.
    Rizzo, M.
    De Giorgi, U.
    Antonuzzo, L.
    Bracarda, S.
    Carteni, G.
    Atzori, F.
    Tamberi, S.
    Procopio, G.
    Fratino, L.
    Santoni, M.
    Baldessari, C.
    Astone, A.
    Calabro', F.
    Buti, S.
    Fornarini, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S709 - S709
12